LEADER 01639nam 2200457 450 001 9910159537403321 005 20230803035438.0 010 $a1-62387-414-9 035 $a(CKB)3710000000264895 035 $a(EBL)1817203 035 $a(SSID)ssj0001399613 035 $a(PQKBManifestationID)11908576 035 $a(PQKBTitleCode)TC0001399613 035 $a(PQKBWorkID)11457563 035 $a(PQKB)11440004 035 $a(MiAaPQ)EBC1817203 035 $a(EXLCZ)993710000000264895 100 $a20141111h20132013 uy 1 101 0 $apor 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAprendendo a pensar sobre perseveranca $euma histo?ria sobre perseveranca /$fSalem de Bezenac 210 1$a[Paris, France] :$c[iCharacter],$d[2013] 210 4$dİ[2013] 215 $a1 online resource (32 p.) 300 $aDescription based upon print version of record. 311 08$aPrint version: de Bezenac, Salem. Aprendendo a pensar sobre perseveranca : uma histo?ria sobre perseveranca. [Paris, France] : [iCharacter], c[2013] approximately 32 pages 9781623874148 330 $a Learning new things can be a challenge. Roby learns to keep on trying and practicing until he finally makes it. Suggested for ages 6 and younger. 606 $aPerseverance (Ethics)$vFiction 615 0$aPerseverance (Ethics) 676 $a398.2 700 $ade Bezenac$b Salem$01076923 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910159537403321 996 $aAprendendo a pensar sobre perseveranca$93410957 997 $aUNINA LEADER 06053nam 2201789z- 450 001 9910372785603321 005 20210212 010 $a3-03921-849-2 035 $a(CKB)4100000010163770 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/61237 035 $a(oapen)doab61237 035 $a(EXLCZ)994100000010163770 100 $a20202102d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aTransmucosal Absorption Enhancers in the Drug Delivery Field 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (406 p.) 311 08$a3-03921-848-4 330 $aDevelopment of strategies to assist the movement of poorly permeable molecules across biological barriers has long been the goal of drug delivery science. In the last three decades, there has been an exponential increase in advanced drug delivery systems that aim to address this issue. However, most proprietary delivery technologies that have progressed to clinical development are based on permeation enhancers (PEs) that have a history of safe use in man. This Special Issue entitled "Transmucosal Absorption Enhancers in the Drug Delivery Field" aims to present the current state-of-the-art in the application of PEs to improve drug absorption. Emphasis is placed on identification of novel permeation enhancers, mechanisms of barrier alteration, physicochemical properties of PEs that contribute to optimal enhancement action, new delivery models to assess PEs, studies assessing safety of PEs, approaches to assist translation of PEs into effective oral, nasal, ocular and vaginal dosage forms and combining PEs with other delivery strategies. 606 $aMedicine$2bicssc 610 $aabsorption enhancement 610 $aabsorption enhancer 610 $aabsorption enhancers 610 $aabsorption modifying excipients 610 $aAloe vera 610 $aamino acid 610 $aamphiphilic polymers 610 $aand liposome 610 $aantiepileptic drug 610 $aantimicrobial peptide 610 $abiocompatibility studies 610 $abioenhancer 610 $ablock copolymers 610 $abrush border 610 $aCaco-2 610 $aCaco-2 cells 610 $acationic functionalization 610 $acell-penetrating peptide 610 $acell-penetrating peptide (CPP) 610 $acervicovaginal tumors 610 $achitosan 610 $achitosan derivatives 610 $aclaudin 610 $aclinical trial 610 $aCNS disorders 610 $acombined microsphere 610 $acompound 48/80 610 $aconfocal laser scanning microscopy 610 $acornea 610 $acurcumin 610 $acyclodextrin 610 $acytochrome P450 610 $adrug absorption enhancer 610 $adrug administration 610 $adrug delivery 610 $aefflux 610 $aenterocyte 610 $aepithelial permeability 610 $aepithelial transport 610 $aepithelium 610 $aF-actin 610 $aFITC-dextran 610 $aformulation 610 $agel 610 $agemini surfactant 610 $aGLP-1 610 $ahydrophobization 610 $aimatinib 610 $ain situ hydrogel 610 $ain vivo studies 610 $ainsulin 610 $aintestinal absorption 610 $aintestinal delivery 610 $aintestinal epithelial cells 610 $aintestinal permeation enhancers 610 $aKLAL 610 $aman 610 $amast cell activator 610 $ametabolism 610 $amucoadhesion 610 $amucoadhesiveness 610 $aN-dodecyl-?-D-maltoside (DDM) 610 $ananocapsules 610 $ananocrystals 610 $ananomedicine 610 $ananoparticle 610 $ananoparticles 610 $anasal 610 $anasal delivery 610 $anasal formulation 610 $anasal permeability 610 $anasal vaccination 610 $anose to brain delivery 610 $anose to brain transport 610 $anose-to-brain 610 $aocular conditions 610 $aocular delivery 610 $aocular drug delivery 610 $aophthalmology 610 $aoral delivery 610 $aoral macromolecule delivery 610 $aoral peptides 610 $aosteoporosis 610 $aP-glycoprotein 610 $apenetration enhancer 610 $apenetration enhancers 610 $apermeability 610 $apermeation enhancer 610 $apermeation enhancers 610 $apharmacokinetic interaction 610 $apharmacokinetics 610 $aPN159 610 $apolymeric micelles 610 $apoorly absorbed drug 610 $apreclinical 610 $aPTH 1-34 610 $apulmonary 610 $aquaternization 610 $asafety 610 $asalcaprozate sodium 610 $asheep 610 $asimulated intestinal fluid 610 $asimvastatin 610 $asmall intestine 610 $asodium caprate 610 $asodium cholate (NaC) 610 $asugar-based surfactants 610 $ateriparatide 610 $athermogel system 610 $atight junction 610 $atight junction modulator 610 $atight junctions 610 $atransepithelial electrical resistance 610 $atransferrin 610 $atransmucosal drug delivery 610 $atransmucosal permeation 610 $atryptophan 610 $avaccine adjuvant 610 $avaginal delivery 610 $awhole leaf 615 7$aMedicine 700 $aMaher$b Sam$4auth$01322342 702 $aIllum$b Lisbeth$4auth 702 $aCasettari$b Luca$4auth 906 $aBOOK 912 $a9910372785603321 996 $aTransmucosal Absorption Enhancers in the Drug Delivery Field$93034888 997 $aUNINA